IceCure Medical Granted FDA Breakthrough Device Designation for ProSense(R) Cryoablation System
Treatment for patients with T1 invasive breast cancer and/or breast cancer for patients not suitable for surgical alternatives included in the indications being reviewed
CAESAREA, Israel, April 5, 2021 -- (Healthcare Sales & Marketing Network) -- IceC... Devices, Oncology, FDA IceCure Medical, ProSense , cryoablation
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Israel Health | Marketing | Middle East Health | Pharmaceuticals